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ProfileRegenerating Battle Wounds, TogetherHow many laboratories does it take to
heal the wounded warrior?
In 2008, theU.S.DepartmentofDefense
(DOD) launched the Armed Forces Insti-
tute for Regenerative Medicine, or AFIRM,
a 5 year initiativemodeled on the assump-
tion that bringing together a multi-institu-
tional throng of talent is a far better
approach than adhering to the isolating,
competitive status quo of team versus
team. AFIRM’s mission is to accelerate
the development of therapies for those
who have served, especially those injured
in Iraq and Afghanistan, and since the
DOD was already backing a few ventures
into regenerative medicine—Defense
Advanced Research Projects Agency
(DARPA)’s Restorative Injury Repair
Program, for instance—that became the
new project’s signature mark as well.
AFIRM’s research areas were chosen in
light of a hard truth about modern warfare.
Even though new and improved life-
saving strategies have reduced the
number of fatalities, more soldiers are re-
turning from combat with devastating
wounds that once would have killed
them. AFIRM is less about regenerating
entire parts, and more about using adult
stem cells and progenitors to restore
tissue torn apart by lethal, modern-
day explosives: blast-induced burns andAn unidentified AFIRM researcher at Rutgers University
demonstrates a bone regeneration scaffold (round white object in
foreground). The images on the computer screen represent
magnified CT scans of newly regenerated bone (highlighted in blue)
when the bone regeneration scaffold was used to heal a large
circular defect in the skull of a rabbit in a preclinical model study.
Photo by Don Lindorfer.nerve damage; loss of bone,
muscle, tendons, fingers,
ears, and noses; and deep
wounds to the head and
abdomen.
Today, 4 years down the
line, AFIRM’s multidisciplinary
strengths are more appre-
ciable than ever, notably its
scientists’ quicker than usual
strides toward clinical trials,
and while the initiative has
experienced some rocki-
ness—‘‘When you put 200 to
300 scientists in one boat,
what do you expect?’’ one
researcher remarked—the
DOD plans to renew AFIRM
for another 5 years. An
announcement to that effect
is imminent, said Terry Irgens,
AFIRM’s director since
October 2010.Ship in the Making
Something unique about AFIRM, other
than its sheer size, is its structure.
Researchers at Rutgers University and
the Cleveland Clinic head one network of
15 institutions, while Wake Forest and
the University of Pittsburgh’s McGowan
Institute for Regenerative Medicine head
a second group of 16. Both consortia
also collaborate with scientists at the
U.S. Army Institute of Surgical Research,
and connect with industrial partners who
help open the way to clinical trials.
The U.S. Army Medical Research and
Material Command (MRMC), meanwhile,
is responsible for overseeing the whole
ocean liner andmanaging funds. The orig-
inal DOD funding came to roughly $100
million, with funds coming from the
MRMC in conjunction with the Office of
Naval Research, the NIH, the Air Force
Office of the Surgeon General, and the
Department of Veterans Affairs. In addi-
tion, laboratories themselves brought in
over $100 million, monies that their pro-
jects had attracted from the NIH, the
state, universities, and other sources.
When the initiative was first announced,
seven proposers representing dozens of
institutions went head-to-head for the
grant, the competitive spirit still apparent
at AFIRM’s first meeting. ‘‘I’ve been toldCell Stem Cellthat all the Wake Forest-Pittsburgh scien-
tists sat on one side of the room and
the Rutgers-Cleveland group sat on the
other,’’ Irgens recounted. The two-
prowed vessel ‘‘posed a bit of a dilemma,
as we had to figure out a way for the sepa-
rate groups to work together.’’ Ever since,
the emphasis has been on shedding a
competitive mentality and thinking collab-
oratively. The approximately 75 projects
currently in progress are a testament to
AFIRM’s success.
Collaborative Sailing
The workload is divided into five research
areas—burn repair, scarless wound heal-
ing, craniofacial reconstruction, limb-digit
salvage, and compartment syndrome
repair—which creates plenty of opportu-
nity for investigators to interact. Working
on seven burn-repair projects, for in-
stance, are ten investigators from the
Wake Forest-Pittsburgh consortium,
seven from the Rutgers-Cleveland group,
and four from the Army Institute of
Surgical Research. Each research project
is conducted by either an academic or a
physician scientist, and all projects within
each area of focus are overseen by a
Program Leader.
‘‘What the government model origi-
nally overlooked was the tremendous10, March 2,amount of synergy that is
unleashed when you change
the culture of our scientists
from a competitive nature
into a collaborative nature,’’
said Joachim Kohn, director
of the Rutgers-Cleveland
group. ‘‘To our great delight,
that synergy is creating
many successes.’’
Kohn recounted with great
relish one such instance:
how, through AFIRM’s burn
program, he met Richard
Clark, a Stony Brook derma-
tologist who had developed
a compound that prevents a
burn from progressing from
a second-degree to a third-
degree burn. Kohn, im-
pressed with Clark’s product,
then developed a custom-
designed wound dressing2012 ª2012 Elsevier Inc. 241
The white objects in the picture are bone
regeneration scaffolds in various sizes developed
at Rutgers University under AFIRM funding. In this
photograph, an unidentified researcher attempts to
fit one of the bone regeneration scaffolds into
a defect created in the skull of a rabbit for training
purposes. Photo by Don Lindorfer.
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onto the wound. Kohn then encoun-
tered Thomas Mustoe, a plastic
surgeon from Northwestern Univer-
sity, in the same program, who
applied the wound dressing to his
lab’s rabbit model and showed that
indeed it alleviated scaring.
‘‘No one had a clue such an
outcome was possible,’’ said Kohn.
‘‘Clark, Mustoe, and I didn’t know
each other, and now we are three
peas in a pod.’’
George Muschler of the Cleveland
Clinic noted that a 3 year comparison
of scaffolds for bone defects had ‘‘a
significant benefit’’ for the four labora-
tories involved. ‘‘Labs traditionally
work on their own and don’t aggres-
sively compare their biomaterials.
Each of these labs learned something
important about their scaffold—what
could work better and what wasn’t
working.’’
In a separate project, one related
to craniofacial research, Joseph Va-
canti of Harvard Medical School and
Robert Langer of MIT have been
trying to beat two major problems
that have kept tissue-engineered
ears from the clinic: scaffolding that
cannot withstand the contractile force
of growing tissue, and cartilage cellsources that get resorbed by the body.
‘‘I would say that over the past 4 years, it
appears we have solved both of these
problems,’’ said Vacanti, thanks to fund-
ing and resources from AFIRM, and the
team’s collaboration with ear surgeons
at the Massachusetts Eye and Ear Infir-
mary as well as scientists at Kensey
Nash who have applied their expertise in
cartilage repair devices to the ear for the
very first time.
Just how quickly some products
reached clinical trials surprised everyone.
Eleven trials are underway, according to
Terry Irgens, who expects three more
products to enter Phase 1 trials later this
year. One of the burn-repair technologies,
a sprayable cell treatment, is likely to be
the first product to reach the market as
a direct result of AFIRM.
Ahoy, Clinical Trials
AFIRM has ‘‘far exceeded the very
conservative goal initially set’’ of having
one patient enrolled in a clinical trial
after 5 years, noted Irgens. Already as242 Cell Stem Cell 10, March 2, 2012 ª2012many as 100 patients are enrolled in
several. Because no one had imagined
clinical trials would happen so soon,
the DOD’s original funding for AFIRM,
roughly $100million, had been earmarked
solely for science and technology, said
Irgens.
Then synergy made for shortcuts:
getting rid of duplicate therapies and
inferior approaches, and sharing knowl-
edge and resources whenever possible.
Resources put in place by the DOD further
accelerated projects toward clinical-trial
status. ‘‘We hired an FDA consultant
who was available to all groups within
our consortium,’’ described Kohn. ‘‘We
hired a consultant for final-stage commer-
cialization. We established a central
clinical trial coordinating group under
Dr. Stanton Gerson at Case Western
Reserve to help every group write appro-
priate proposals. Not a single group by it-
self could assemble these resources. If
you want to hire a commercialization
expert on your NIH grant, you’re in
trouble.’’Elsevier Inc.Once it became clear that some
products were ready for human trials,
the government contributed an extra
$20 million for early Phase 1 funding.
Clinical-trial coffers continue to be
added to by newly arriving commer-
cial partners, with AFIRM’s total
funding approaching $300 million.
That cost can be seen as a bargain
in that each developed technology,
as required by the DOD, must meet
a civilian as well as a military need.
While AFIRM’s assemblage of
people and technologies has be-
stowed the potential of fast sailing to
clinical trials, the voyage hasn’t been
without occasional clashes between
captains. ‘‘When you bring people
together who on their own merit are
very successful, they’re used to
leading projects and not necessarily
used to responding quickly to other
people’s ideas,’’ said Stephen Bady-
lak of the McGowan Institute for
Regenerative Medicine, a project
leader in the limb salvage program
for the Wake Forest-Pittsburgh con-
sortium. Moreover, ‘‘issues related
to intellectual property are always
present.’’
A few investigators have opted out
of their leadership roles or left the
project entirely. ‘‘In any large organi-zation,’’ said Muschler, ‘‘where there are
this many highly skilled investigators,
where there’s this much national impera-
tive and this much money concentrated
in one place, there are going to be
disagreements.’’
Heeling Forward
For AFIRM’s next 5 year term, the DOD
will accept new applicants. ‘‘Although
undoubtedly the existing consortia would
like to carry over, we need to do a re-
compete out of a need for fairness,’’
observed Irgens. ‘‘There may be other
universities out there that might have
technologies that are even more
advanced than those currently worked
on.’’ Some scientists in the current round
voiced concern that, because the project
has lacked long-term vision vis-a`-vis
seeing technologies all the way through
the pipeline, some technologies will lose
financial footing and wither on the vine.
Whether or not his lab is chosen for the
next round, Badylak is prepared to do
whatever it takes to continue developing
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missing digits or skeletal muscle, a novel
technique that prompts an accumulationof cells and tissue at the site of injury. Is
he confident that this technique will reach
patients?Cell Stem Cell‘‘Oh yes, absolutely. No question about
it,’’ Badylak said. ‘‘I’d be extremely disap-
pointed if it didn’t.’’Ann Parson*
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